Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
CTXR
CTXR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CTXR News
Citius Pharmaceuticals Rated Highly by Wall Street Analysts
6d ago
Yahoo Finance
Citius Pharmaceuticals Reports Increased Losses in Q2 FY 2026
May 19 2026
NASDAQ.COM
Citius Pharmaceuticals Reports Q2 2026 Financial Results
May 15 2026
seekingalpha
Citius Oncology Reports Q2 2026 Financial Results and Business Update
May 15 2026
PRnewswire
Citius Pharma Reports $5.6 Million Net Revenue in H1 2026
May 15 2026
PRnewswire
Citius Pharma Reports Q2 2026 Financial Results and Business Update
May 15 2026
Newsfilter
Citius Pharmaceuticals Closes $5 Million Registered Direct Offering
Apr 24 2026
PRnewswire
Citius Pharmaceuticals Closes $5 Million Direct Offering
Apr 24 2026
Newsfilter
Citius Pharmaceuticals Enters Stock Sale Agreement
Apr 24 2026
seekingalpha
Citius Pharmaceuticals Completes $5 Million Stock Offering
Apr 24 2026
PRnewswire
Citius Oncology Launches LYMPHIR for Cutaneous T-Cell Lymphoma Treatment
Mar 31 2026
PRnewswire
Citius Oncology Launches LYMPHIR, Advancing Cancer Treatment
Mar 31 2026
Newsfilter
LYMPHIR Shows Promise in Gynecologic Cancer Treatment
Mar 10 2026
PRnewswire
Citius Oncology Reports Positive Phase 1 Trial Results for LYMPHIR in DLBCL
Mar 04 2026
PRnewswire
Citius Oncology Reports Positive Phase 1 Trial Results for LYMPHIR in DLBCL
Mar 04 2026
Newsfilter
Citius Pharmaceuticals Reports $3.9 Million Revenue in Q1 2026
Feb 13 2026
PRnewswire
Show More News
